NCT06256510View on ClinicalTrials.gov

A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam

PHASE1CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 8, 2024

Primary Completion Date

April 16, 2024

Study Completion Date

May 13, 2024

Conditions
Healthy Participants
Interventions
DRUG

Midazolam

Participants will receive a single dose of Midazolam by mouth in Period 1 Day 1, and Period 2 Day 1 and Day 15

DRUG

Vepdegestrant

Participants will receive Vepdegestrant by mouth once a day for 15 days in Period 2.

Trial Locations (1)

B-1070

Pfizer Clinical Research Unit - Brussels, Brussels

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

Arvinas Estrogen Receptor, Inc.

INDUSTRY

lead

Pfizer

INDUSTRY

NCT06256510 - A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam | Biotech Hunter | Biotech Hunter